Skip to main content
2023 Guide to Patient Support Services


2023 PSS Guide

The Organon Access Program


Organon offers The Organon Access Program to assist patients who have been prescribed Ontruzant (Table).

The Organon Access Program

The Organon Access Program can assist with benefit investigation, prior authorizations, the appeal process, and offers the Organon Co-pay Assistance Program as well as the Organon Patient Assistance Program.

The Organon Co-pay Assistance Program

Once enrolled, eligible, privately insured patients pay the first $5 of their copay per infusion. The maximum copay assistance program benefit is $25,000 per patient, per calendar year. Patients may be eligible for copay assistance if they:

  • Are a resident of the United States
  • Have private health insurance that provides coverage for Ontruzant under a medical benefit program
  • Have been prescribed Ontruzant for an FDA-approved indication
  • Are not covered under a government program as that term is defined in the Terms and Conditions
  • Meet all other terms and conditions of the program.

The Organon Patient Assistance Program

The Organon Patient Assistance Program is primarily designed to help those who do not have insurance coverage; however, if your patient has insurance coverage for Ontruzant, including Medicare Part D, but still has trouble paying for their medicine, they may request that an exception be made, provided their income is not above a set limit and they meet certain other medical and/or insurance criteria. Patients may be eligible if they:

  • Are a US resident and have a prescription for Ontruzant from a healthcare provider licensed in the United States
  • Do not have insurance or other coverage for a prescription medicine
  • Cannot afford to pay for their medicine and have a household income of $64,400 or less for individuals, $87,100 or less for couples, or $132,500 or less for a family of 4.

Click here for more information on The Organon Patient Assistance Program, or call 888-727-0015.

TABLE Organon Oncology Drug

Patient support programs

Ontruzant (trastuzumab-dttb)
Adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or as part of a treatment regimen with docetaxel and carboplatin, or as a single agent following multimodality anthracycline-based therapy; in combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer; as a single agent for treatment of HER2-overexpressing breast cancer in patients who have received ≥1 chemotherapy regimens for metastatic disease; in combination with cisplatin and capecitabine or 5-fluorouracil for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"